SubscribeLogin
Published

Nagase Viita to Launch SUCROSE SG, an Injectable-Grade Pharmaceutical Excipient, in 2025 - Pharma Excipients

Summary by Pharma Excipients
PRESS RELEASE Nagase Viita Co., Ltd. (Headquarters: Shimoishii, Kita-ku, Okayama; Representative Director: Naoki Yasuba), a member of the NAGASE Group, is set to expand the line of SOLBIOTETM, saccharide-based pharmaceutical excipients, with the launch of high-purity and low-endotoxin SUCROSE SG by June 2025. The portfolio of SOLBIOTETM includes TREHALOSE SG and MALTOSE PH which are the signature products of pharmaceutical ingredients, and with …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

OkayamaOkayama
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal